AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9210608
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of terlipressin (1-2 mg, i.v. bolus) with ANP (35 ng/kg, i.v. bolus followed by 15 ng x kg(‐1) x min(‐1) for 60 min)
Trial: 9210608
Drug: Terlipressin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin alone (1-2 mg, i.v. bolus)
Trial: 7957341
Drug: Chemotherapy (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (after PAC or CAC therapy)
Trial: 29333870
Drug: Control (usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (usual daily activities)
Trial: 22682723
Drug: 24/4 regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24/4 regimen (20 mcg ethinyl estradiol and 1 mg norethindrone acetate)
Trial: 22682723
Drug: 21/7 regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21/7 regimen (20 mcg ethinyl estradiol and 1 mg norethindrone acetate)
Trial: 15593189
Drug: OPC‐28326 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC‐28326 40 mg
Trial: 15593189
Drug: OPC‐28326 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC‐28326 10 mg
Trial: 11340365
Drug: Intranasal CCK-8
RxNorm normalized name: CCK-8
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal CCK-8
Trial: 3036715
Drug: Acyclovir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (800 mg five times daily) for seven days
Trial: 3036715
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir (10 mg/kg three times daily) combined with prednisolone (0.7 mg/kg daily) for ten days
Trial: 27005766
Drug: TABLETS intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TABLETS intervention
Trial: 24748531
Drug: CAF +
RxNorm normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAF + CHO (6 mg kg(-1) BW caffeine and 0.8 g kg(-1) BW carbohydrate)
Trial: 17012983
Drug: Levetiracetam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (mean maximum dosage 862.50±279.19 mg/day)
Trial: 31706345
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (twice per week for 12 sessions at specified acupoints)
Trial: 25275577
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine (bolus 1.5 mg/kg at induction, then infusion at 2 mg/kg/h, stopped 2 hours after surgery)
Trial: 25493600
Drug: Daily infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily infant nevirapine
Trial: 12934987
Drug: Oral-loaded divalproex
RxNorm normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-loaded divalproex (20 or 30 mg/kg/day on days 1 and 2 followed by 20 mg/kg/day)
Trial: 12934987
Drug: Oral-loaded divalproex
RxNorm normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-loaded divalproex
Trial: 12934987
Drug: Standard-titration divalproex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-titration divalproex
Trial: 8602748
Drug: Anticoagulants (international
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants (international normalized ratio range, 2.8-4.8)
Trial: 1394813
Drug: Early instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early instillation of Adriamycin with oral administration of 5-fluorouracil (Group B)
Trial: 1394813
Drug: Delayed instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed instillation of Adriamycin with oral administration of 5-fluorouracil (Group D)
Trial: 2983151
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy and oral Levamisole
Trial: 2983151
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy only
Trial: 30213449
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus androgen deprivation therapy
Trial: 28627930
Drug: Fenofibrate 100
RxNorm normalized name: fenofibrate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 100 mg
Trial: 25864750
Drug: Iontophoresis of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophoresis of the Chinese drug
Trial: 23524368
Drug: Structured injury
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured injury prevention program performed twice weekly for the entirety of the season (58 prevention sessions)
Trial: 17877674
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol (50 micrograms)
Trial: 12006420
Drug: Formoterol (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (12 microg twice daily)
Trial: 6367635
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate lozenges (23 mg, dissolved every 2 hours after an initial double dose)
Trial: 24286966
Drug: Stimulant Abuser
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant Abuser Groups to Engage in 12-Step (STAGE-12) intervention
Trial: 15781758
Drug: Isotretinoin high
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin high dose (1.0 mg/kg per day) for 1 year followed by moderate dose (0.5 mg/kg per day) for 2 years
Trial: 15781758
Drug: Isotretinoin moderate
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin moderate dose (0.5 mg/kg per day) for 3 years
Trial: 8879891
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of cefdinir once daily (QD) for 10 days
Trial: 8879891
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of cefdinir twice daily (BID) for 10 days
Trial: 1379664
Drug: Cisplatin 80
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 80 mg/M2 on day 1 and 5-fluorouracil 800 mg/M2 days 2 through 6 (two-drug regimen)
Trial: 1379664
Drug: Cisplatin 80
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 80 mg/M2 on day 1, 5-fluorouracil 800 mg/M2 days 2 through 6, plus 15 U bleomycin on day 1 and methotrexate 100 mg/M2 on day 16 followed by 15 mg leucovorin every 6 hours for six doses (four-drug regimen)
Trial: 30600702
Drug: HIV-1 vaccine
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 vaccine only
Trial: 30600702
Drug: IL-2, GM-CSF,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2, GM-CSF, and rhGH immunotherapy with or without vaccine
Trial: 25891091
Drug: Triple anti-platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple anti-platelet therapy (TAT; aspirin, clopidogrel, and sarpogrelate)
Trial: 25891091
Drug: Conventional dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dual antiplatelet therapy (DAT; aspirin and clopidogrel)
Trial: 23663651
Drug: Integrated cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated cognitive behavioral therapy (CBT) - 15 sessions directed at symptom reduction of SUD and ADHD
Trial: 23663651
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual - 10 CBT sessions directed at symptom reduction of SUD only
Trial: 20303665
Drug: Pregabalin (12-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (12-week treatment)
Trial: 17593025
Drug: Low-dose gemtuzumab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose gemtuzumab ozogamicin (GO) added to FLAI chemotherapy
Trial: 17593025
Drug: Low-dose gemtuzumab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose gemtuzumab ozogamicin (GO)
Trial: 17593025
Drug: FLAI chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLAI chemotherapy without GO (historical cohort)
Trial: 17966028
Drug: Cast treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cast treatment
Trial: 12468610
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplements
Trial: 9812128
Drug: Right prefrontal
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right prefrontal transcranial magnetic stimulation at 20 Hz (2-second duration per train, 20 trains/day for 10 treatment days)
Trial: 9812128
Drug: Left prefrontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left prefrontal transcranial magnetic stimulation at 20 Hz (2-second duration per train, 20 trains/day for 10 treatment days)
Trial: 21729566
Drug: G‐CSF during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF during the steady rise of the WBC count (5 µg/kg subcutaneously until final PBSC apheresis)
Trial: 21729566
Drug: G‐CSF subcutaneously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF subcutaneously (filgrastim) at the first restoration after the initial nadir of the peripheral WBC count (historical control group)
Trial: 16723054
Drug: Prilocaine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prilocaine (300 or 400 mg)
Trial: 9376990
Drug: cA2 (chimeric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cA2 (chimeric monoclonal antibody)
Trial: 7680852
Drug: Normothermic bypass
RxNorm normalized name: factor VIII inhibitor bypassing activity
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normothermic bypass and administration of high‐dose aprotinin (2 million IU before CPB, 500,000 IU/h until the end of the operation, and 2 million IU added to the prime)
Trial: 3531052
Drug: Trestatin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trestatin 10 mg
Trial: 3531052
Drug: Trestatin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trestatin 3 mg
Trial: 3531052
Drug: Trestatin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trestatin 50 mg
Trial: 24168957
Drug: Aggressive medical
RxNorm normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive medical management (antiplatelet therapy, intensive management of vascular risk factors, lifestyle-modification programme)
Trial: 20521033
Drug: Dalcetrapib 3,900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalcetrapib 3,900 mg
Trial: 15643191
Drug: Topical 0.2%
RxNorm normalized name: coal tar topical 0.2% topical soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.2% glyceryl trinitrate (GTN) paste
Trial: 7779733
Drug: Accelerated radiotherapy
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated radiotherapy (55 Gy in 32-36 fractions of 1.72-1.53 Gy, twice daily for 3 weeks)
Trial: 2264602
Drug: Volunteers for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers for treatment study
Trial: 2264602
Drug: Non-volunteers for
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-volunteers for treatment study
Trial: 6756508
Drug: Tamoxifen plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen plus CMF chemotherapy
Trial: 31654573
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg ARC-520
Trial: 31654573
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg ARC-520
Trial: 27564385
Drug: Anticholinergic medications
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic medications (AC)
Trial: 25380901
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose tacrolimus (group I)
Trial: 25380901
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose tacrolimus (group II)
Trial: 19594741
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of neoadjuvant hormone therapy (NHT) with goserelin acetate and flutamide before radical prostatectomy (RP)
Trial: 17631708
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus imported LMWH treatment group
Trial: 17631708
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus indigenous LMWH treatment group
Trial: 15681099
Drug: Carbohydrate drink
RxNorm normalized name: Ensure Pre-Surgery Clear Carbohydrate Drink (Strawberry)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate drink (CHOD) 12.6g/100ml, 800 ml evening before surgery and 400 ml on the day of surgery 2-3 hours before anaesthesia.
Trial: 15681099
Drug: Placebo drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drink (control group), 800 ml evening before surgery and 400 ml on the day of surgery 2-3 hours before anaesthesia.
Trial: 11947915
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg daily for 16 weeks
Trial: 11947915
Drug: Gemfibrozil 1200
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 1200 mg daily for 16 weeks
Trial: 10487682
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose test (LDT)
Trial: 10487682
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose test (SDT)
Trial: 6345373
Drug: Nitrendipine 40
RxNorm normalized name: nitrendipine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 40 mg
Trial: 6345373
Drug: Nitrendipine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (both doses)
Trial: 29338073
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of androgen deprivation therapy (ADT)
Trial: 26606872
Drug: Sensory approach
RxNorm normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sensory approach combined with traditional swallowing therapy
Trial: 26606872
Drug: Motor approach
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor approach combined with traditional swallowing therapy
Trial: 22595020
Drug: Ubiquinone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinone (400 mg daily for 12 weeks)
Trial: 1255309
Drug: Ampicillin treatment
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin treatment
Trial: 31840813
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (SBP target below 120 mm Hg)
Trial: 31840813
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (SBP target below 140 mm Hg)
Trial: 25008145
Drug: Real tDCS
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real tDCS treatment (2 mA, 35 cm2, two times daily stimulation for 13 min with a 20‐min interval for five consecutive days)
Trial: 25008145
Drug: Real tDCS
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real tDCS treatment
Trial: 22835219
Drug: DHEA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA supplementation (25 mg three times daily for 3 months)
Trial: 19444613
Drug: Acute intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute intake of 15 g of dietary fiber rich in phenolic antioxidants
Trial: 17561952
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) at a starting dose of 12.5 mg/day, target dose of 50 mg/day for patients <30 kg and 75 mg/day for patients >30 kg over 4 weeks
Trial: 17561952
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) at a starting dose of 10 mg/kg/day, target dose of 20 mg/kg/day over 4 weeks
Trial: 17561952
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) at minimum target dose
Trial: 10836730
Drug: Valsartan, 80
RxNorm normalized name: Valsartan, 80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan, 80 mg, o.d. (AT1 antagonist)
Trial: 30626650
Drug: l-serine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-serine (400 mg/kg/day)
Trial: 28435240
Drug: Budesonide-containing treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide-containing treatments (budesonide/formoterol or budesonide)
Trial: 28435240
Drug: Non-budesonide-containing treatments
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Non-budesonide-containing treatments (formoterol or placebo)
Trial: 24909399
Drug: Bipolar transurethral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bipolar transurethral resection of the prostate (B‐TURP) using the TURis system in patients with prostate volume >70 mL
Trial: 24909399
Drug: Monopolar transurethral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monopolar transurethral resection of the prostate (M‐TURP) in patients with prostate volume >70 mL
Trial: 24909399
Drug: Bipolar transurethral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bipolar transurethral resection of the prostate (B‐TURP) using the TURis system in patients with prostate volume ≤ 70 mL
Trial: 23800443
Drug: Supportive text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive text messages delivered twice daily for three months (n=24)
Trial: 12868009
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (1 g/day)
Trial: 22253969
Drug: High Dairy
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dairy (HD; three dairy servings, diet totaling 1,400 mg/day)
Trial: 22253969
Drug: High Calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Calcium (HC; 1,400 mg/day)
Trial: 22253969
Drug: Low Calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Calcium (LC; 600 mg/day)
Trial: 11434192
Drug: Simvastatin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (both doses)
Trial: 10024195
Drug: Self-reported exposures
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported exposures to pesticides, debris from Scuds, chemical and biological warfare agents, and smoke from tent heaters
Trial: 8311291
Drug: Both ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both ranitidine 50 mg and metoclopramide 10 mg
Trial: 30347089
Drug: Anticoagulant only
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant only
Trial: 30347089
Drug: Both aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both aspirin and anticoagulant
Trial: 26849409
Drug: Substance abuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance abuse program contract within a residential drug treatment program
Trial: 26849409
Drug: Spent 90
RxNorm normalized name: Scented Mayweed Flower
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spent 90 days or greater in a residential drug treatment program
Trial: 19151303
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch (HES) group received 500 mL of saline plus 500 mL of 6% HES 130/0.4
Trial: 19151303
Drug: Saline group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline group received 500 mL saline
Trial: 16864812
Drug: Chronic Kidney
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic Kidney Disease (CKD) defined by a glomerular filtration rate < or =60 mL/minute/1.73 m2
Trial: 15669380
Drug: Pyriproxyfen treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyriproxyfen treatment at 0.01 mg active ingredient/liter